Buy Now
Protein Sequencing Market Size, Share, Growth & Industry Analysis, By Product & Service (Instruments, Reagents & Consumables, Software, Services), By Technology (Mass Spectrometry, Edman Degradation, Hybrid Approaches), By Application (Biopharmaceuticals, Academic & Research Institutes), and Regional Analysis, 2024-2031
Pages: 190 | Base Year: 2023 | Release: April 2025 | Author: Sunanda G.
The market encompasses technologies for determining tprotein amino acid sequence, essential for structural and functional analysis. Advanced solutions, including reagents, sequencing kits, and bioinformatics tools, enhance accuracy.
Key applications span drug discovery, biomarker identification, and proteomics research, supporting advancements in personalized medicine and biotechnology. It plays a crucial role in understanding protein interactions, post-translational modifications, and disease mechanisms across pharmaceutical, clinical, and academic research settings.
The global protein sequencing market size was valued at USD 1231.5 million in 2023 and is projected to grow from USD 1,279.9 million in 2024 to USD 1,743.8 million by 2031, exhibiting a CAGR of 4.52% during the forecast period.
This growth is fueled by its critical role in drug discovery and biomarker identification. Rising proteomics research initiatives in both public and private sectors are advancing sequencing technologies, enhancing insights into protein structures and functions.
Additionally, the increasing adoption of proteomics in clinical diagnostics and disease research is expanding its applications in precision medicine, facilitating early disease detection and targeted therapeutic development.
Major companies operating in the protein sequencing industry are Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Shimadzu Corporation, Rapid Novor, Inc., Charles River Laboratories International, Inc., Proteome Factory AG, Merck KGaA, Bruker Corporation, Fujifilm Holdings Corporation, Bio-Rad Laboratories, Inc., Bioinformatics Solutions Inc., PerkinElmer, Inc., Oxford Nanopore Technologies plc, Waters Corporation, QIAGEN N.V., and others.
Pharmaceutical companies are leveraging sequencing technologies to analyze disease-associated proteins, enabling the development of targeted therapeutics. Proteomic insights aid in identifying novel drug targets, improving treatment efficacy and patient outcomes.
Biomarker discovery supports early disease detection and personalized medicine initiatives, fueling demand for sequencing solutions. The rise of biologics and antibody-based therapies further expands the market. Growing R&D investments in precision medicine establish protein sequencing as an essential tool in next-generation drug development.
Market Driver
Rising Proteomics Research Initiatives
The protein sequencing market is expanding due to the growing use of proteomics in clinical diagnostics and disease research. Sequencing technologies aid in idenfying disease-associated proteins, enabling early detection of conditions such as cancer, neurological disorders, and infectious diseases.
Clinical laboratories are integrating sequencing solutions for diagnostic biomarker validation and patient stratification. Proteomic insights enhance the understanding of disease progression, guiding targeted therapeutic interventions.
Research initiatives focused on rare and complex diseases are boosting demand for sequencing-based proteomic analysis. The increasing reliance on proteomics in precision medicine is propelling growth in healthcare and diagnostics.
Market Challenge
Data Complexity and Interpretation Challenges
The protein sequencing market faces challenges due to the complexity of data generated from high-throughput sequencing platforms. The vast volume of proteomic data requires advanced bioinformatics tools for accurate interpretation, making data processing a bottleneck in research and clinical applications.
To address this, companies are investing in AI-driven bioinformatics solutions, cloud-based data analysis platforms, and machine learning algorithms to enhance data accuracy and streamline analysis.
Additionally, strategic collaborations with computational biology firms are facilitating the integration of automated workflows, enabling faster and more precise protein identification and functional analysis, thereby improving the scalability of proteomics research.
Market Trend
Increasing Adoption of Proteomics in Clinical Diagnostics and Disease Research
The increasing focus on proteomics research is accelerating the growth of the market. Government agencies and private organizations are allocating substantial funding to advance proteomic studies, fostering innovation in sequencing technologies. Large-scale research projects are leading to a strong demand for high-throughput sequencing solutions.
Academic institutions and research laboratories are adopting advanced sequencing platforms to explore protein structures, interactions, and functions. Strategic collaborations between public research institutes and biotechnology firms are expanding access to cutting-edge sequencing tools, promoting continuous technological advancements.
Segmentation |
Details |
By Product & Service |
Instruments, Reagents & Consumables, Software, Services |
By Technology |
Mass Spectrometry, Edman Degradation, Hybrid Approaches |
By Application |
Biopharmaceuticals, Academic & Research Institutes, Clinical Diagnostics, Others |
By Region |
North America: U.S., Canada, Mexico |
Europe: France, UK, Spain, Germany, Italy, Russia, Rest of Europe | |
Asia-Pacific: China, Japan, India, Australia, ASEAN, South Korea, Rest of Asia-Pacific | |
Middle East & Africa: Turkey, UAE, Saudi Arabia, South Africa, Rest of Middle East & Africa | |
South America: Brazil, Argentina, Rest of South America |
Market Segmentation
Based on region, the global market has been classified into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.
The North America protein sequencing market share stood at around 34.09% in 2023, valued at USD 419.8 million. The increasing prevalence of cancer, Alzheimer’s disease, and autoimmune disorders in North America is fueling the demand for protein sequencing in biomarker discovery.
Top research institutions and cancer centers in the region are leveraging sequencing technologies to identify disease-specific protein signatures, enabling early diagnosis and targeted therapy development.
Moreover, the regional market is benefiting from numerous strategic collaborations between biotech firms, pharmaceutical companies, and academic research centers. Leading organizations, including Harvard Medical School, MIT, Stanford University, and the Broad Institute, are partnering with industry players to advance proteomics research and sequencing technology development.
These collaborations facilitate large-scale protein mapping projects, improve sequencing accuracy, and support the commercialization of innovative sequencing solutions, accelerating advancements in proteomics and strengthening the region's market position.
The increasing focus on precision medicine in the U.S. and Canada is further fueling the adoption of sequencing-based proteomic analysis to identify therapeutic targets and develop personalized treatment strategies. Regulatory support for biologic drug approvals and growing investments in next-generation therapeutics are aiding regional market progress.
Asia Pacific protein sequencing industry is estimated to grow at a CAGR of 5.18% over the forecast period. Asia Pacific is at the forefront of biomanufacturing, supported by substantial investments in proteomics infrastructure. Governments and private enterprises in China, India, and Australia are advancing proteomics research with high-throughput sequencing platforms to enhance biologic drug development.
Biomanufacturing hubs in Singapore and South Korea are leveraging protein sequencing for cell line development, recombinant protein production, and stringent quality control processes.
The expansion of biotech incubators and proteomics-focused R&D facilities is accelerating innovations in protein characterization, promoting the widespread adoption of sequencing technologies within the pharmaceutical and biopharmaceutical industries.
The protein sequencing industry is characterized by several market players focused on technological advancements to enhance proteomic analysis accuracy and depth. The integration of next-generation sequencing software with de novo sequencing capabilities enables precise identification of protein variants and structural modifications.
Companies are also leveraging high-resolution mass spectrometry and multi-level sequencing approaches to improve data interpretation and protein characterization.
These advancements are boosting the adoption of protein sequencing solutions in research and clinical applications, expanding market opportunities. Ongoing improvements in sequencing platforms are further advancing biomarker discovery and therapeutic development.
Recent Developments (Product Launch)